Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 20/20 | 0.66 |
| ▸ | BMPR1A | P36894 | 20/20 | 0.66 |
| ▸ | ACVRL1 | P37023 | 20/20 | 0.66 |
| ▸ | ACVR1 | Q04771 | 20/20 | 0.66 |
| ▸ | TGFBR1 | P36897 | 19/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27407318 | 1.00 | BMPR1B (0.66) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21027200 | 1.00 | BMPR1B (0.66) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL24318151 | 0.93 | BMPR1B (0.63) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21027223 | 0.89 | BMPR1B (0.67) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21026978 | 0.89 | BMPR1B (0.69) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL22456040 | 0.89 | BMPR1B (0.68) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21026973 | 0.87 | BMPR1B (0.69) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL19806935 | 0.86 | BMPR1B (0.69) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL23418794 | 0.85 | BMPR1B (0.66) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21027496 | 0.85 | BMPR1B (0.69) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710980-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | BMPR1B 31/4885BMPR1A 64/4885ACVRL1 7/4885 |
| US-20190161474-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR2B, ACVR1B | BMPR1B 31/4885BMPR1A 64/4885ACVRL1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.